Skip to main content
SpringerLink
Log in

Pharmacogenomics of Gynecological Disorders

  • Chapter
  • First Online:
Book cover Omics for Personalized Medicine

  • 1887 Accesses

Abstract

Pharmacogenomics aims to identify the genome-based variability in drug disposition (metabolism and transport), which influences its efficacy and toxicity, and also to develop diagnostics and therapeutics on the basis of genetic variants so as individualize pharmacotherapy. Progress made in the last two decades in pharmacogenomics study of gynecological diseases has enabled us to predict the therapy outcome on the basis of inherited or acquired genetic mutations. The present chapter focuses on the clinical relevance of genetic variation in terms of diagnosis, prognosis, and therapeutics in context to this group of diseases with special reference to gynecological cancers. Various disease susceptibility genes and their polymorphisms of gynecological disorders have been identified, and their molecular diagnostics and targeted therapies developed. To name a few well studied are BRCA1/2, HER2, GSTT1, GSTM1, CYP1B1, PPAR-γ, VEGF, etc. Detailed account of the genetic components and their variants associated with each disease and how it influences the discourse of the disease and individualization of the therapy is given here.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Aglund K, Rauvala M, Puistola U, Angstrom T, Turpeenniemi-Hujanen T, Zackrisson B, Stendahl U (2004) Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer-MMP-9 correlates to the grade and the stage. Gynecol Oncol 94:699–704

    CAS  PubMed  Google Scholar 

  • Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T (1986) The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232:1644–1646

    CAS  PubMed  Google Scholar 

  • Ambrosone CB (2007) The promise and limitations of genome-wide association studies to elucidate the causes of breast cancer. Breast Cancer Res 9:114

    PubMed Central  PubMed  Google Scholar 

  • Arngrimsson R, Hayward C, Nadaud S, Baldursdottir A, Walker JJ, Liston WA, Bjarnadottir RI, Brock DJ, Geirsson RT, Connor JM, Soubrier F (1997) Evidence for a familial pregnancy-induced hypertension locus in the eNOS-gene region. Am J Hum Genet 61:354–362

    CAS  PubMed Central  PubMed  Google Scholar 

  • Arts HJ, Katsaros D, de Vries EG, Massobrio M, Genta F, Danese S, Arisio R, Scheper RJ, Kool M, Scheffer GL, Willemse PH, van der Zee AG, Suurmeijer AJ (1999) Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin Cancer Res 5:2798–2805

    CAS  PubMed  Google Scholar 

  • Ashworth A (2008) A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26:3785–3790

    CAS  PubMed  Google Scholar 

  • Ayoub N, Lucas C, Kaddoumi A (2011) Genomics and pharmacogenomics of breast cancer: current knowledge and trends. Asian Pac J Cancer Prev 12:1127–1140

    PubMed  Google Scholar 

  • Badawi AF, Cavalieri EL, Rogan EG (2001) Role of human cytochrome P450 1A1, 1A2, 1B1, and 3A4 in the 2-, 4-, and 16alpha-hydroxylation of 17beta-estradiol. Metabolism 50:1001–1003

    CAS  PubMed  Google Scholar 

  • Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J (1998) Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58:2825–2831

    CAS  PubMed  Google Scholar 

  • Baumwell S, Karumanchi SA (2007) Pre-eclampsia: clinical manifestations and molecular mechanisms. Nephron Clin Pract 106:c72–c81

    PubMed  Google Scholar 

  • Bereketoglu C, Kasap M, Pazarbasi A (2012) Studies on Angiotensin-converting enzyme insertion/deletion polymorphism and genotype distributions in Turkish preeclampsia patients. J Pregnancy 2012:108206

    PubMed Central  PubMed  Google Scholar 

  • Bogusiewicz M, Stryjecka-Zimmer M, Postawski K, Jakimiuk AJ, Rechberger T (2007) Activity of matrix metalloproteinase-2 and -9 and contents of their tissue inhibitors in uterine leiomyoma and corresponding myometrium. Gynecol Endocrinol 23:541–546

    CAS  PubMed  Google Scholar 

  • Bombell S, McGuire W (2008) Tumour necrosis factor (-308A) polymorphism in pre-eclampsia: meta-analysis of 16 case-control studies. Aust N Z J Obstet Gynaecol 48:547–551

    PubMed  Google Scholar 

  • Bosch TM, Huitema AD, Doodeman VD, Jansen R, Witteveen E, Smit WM, Jansen RL, van Herpen CM, Soesan M, Beijnen JH, Schellens JH (2006) Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin Cancer Res 12:5786–5793

    CAS  PubMed  Google Scholar 

  • Broomall EM, Reynolds SM, Jacobson RM (2010) Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus. Postgrad Med 122:121–129

    PubMed  Google Scholar 

  • Buchanan TA (2001) Pancreatic B-cell defects in gestational diabetes: implications for the pathogenesis and prevention of type 2 diabetes. J Clin Endocrinol Metab 86:989–993

    CAS  PubMed  Google Scholar 

  • Calhoun ES, McGovern RM, Janney CA, Cerhan JR, Iturria SJ, Smith DI, Gostout BS, Persing DH (2002) Host genetic polymorphism analysis in cervical cancer. Clin Chem 48:1218–1224

    CAS  PubMed  Google Scholar 

  • Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625–1638

    PubMed  Google Scholar 

  • Cameron D, Casey M, Oliva C, Newstat B, Imwalle B, Geyer CE (2010) Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 15:924–934

    CAS  PubMed Central  PubMed  Google Scholar 

  • Catalano PM, Tyzbir ED, Wolfe RR, Roman NM, Amini SB, Sims EA (1992) Longitudinal changes in basal hepatic glucose production and suppression during insulin infusion in normal pregnant women. Am J Obstet Gynecol 167:913–919

    CAS  PubMed  Google Scholar 

  • Chatterjee K, Engelmark M, Gyllensten U, Dandara C, van der Merwe L, Galal U, Hoffman M, Williamson AL (2009) Fas and FasL gene polymorphisms are not associated with cervical cancer but differ among Black and Mixed-ancestry South Africans. BMC Res Notes 2:238

    PubMed Central  PubMed  Google Scholar 

  • Chen ZP, Malapetsa A, Monks A, Myers TG, Mohr G, Sausville EA, Scudiero DA, Panasci LC (2002) Nucleotide excision repair protein levels vis-a-vis anticancer drug resistance in 60 human tumor cell lines. Ai Zheng 21:233–239

    PubMed  Google Scholar 

  • Cho YM, Kim TH, Lim S, Choi SH, Shin HD, Lee HK, Park KS, Jang HC (2009) Type 2 diabetes-associated genetic variants discovered in the recent genome-wide association studies are related to gestational diabetes mellitus in the Korean population. Diabetologia 52:253–261

    CAS  PubMed  Google Scholar 

  • Colacurci N, De Seta L, De Franciscis P, Mele D, Fortunato N, Cassese S (2000) Tamoxifen effects on endometrium. Panminerva Med 42:45–47

    CAS  PubMed  Google Scholar 

  • Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U et al (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132–1139

    CAS  PubMed  Google Scholar 

  • Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM (2002) Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos 30:869–874

    CAS  PubMed  Google Scholar 

  • Criscitiello C, Metzger-Filho O, Saini KS et al (2012) Targeted therapies in breast cancer: are heart and vessels also being targeted? Breast Cancer Res 14:209

    CAS  PubMed Central  PubMed  Google Scholar 

  • Cui Z, Huang L (2005) Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer. Cancer Immunol Immunother 54:1180–1190

    CAS  PubMed  Google Scholar 

  • Czernobilsky B, Lifschitz-Mercer B (1997) Endometrial pathology. Curr Opin Obstet Gynecol 9:52–56

    CAS  PubMed  Google Scholar 

  • Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E (1992) ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84:1512–1517

    CAS  PubMed  Google Scholar 

  • Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E (1994) Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94:703–708

    CAS  PubMed Central  PubMed  Google Scholar 

  • De Miranda J, Panizzutti R, Foltyn VN, Wolosker H (2002) Cofactors of serine racemase that physiologically stimulate the synthesis of the N-methyl-D-aspartate (NMDA) receptor coagonist D-serine. Proc Natl Acad Sci U S A 99:14542–14547

    PubMed Central  PubMed  Google Scholar 

  • de Pace V, Chiossi G, Facchinetti F (2007) Clinical use of nitric oxide donors and L-arginine in obstetrics. J Matern Fetal Neonatal Med 20:569–579

    PubMed  Google Scholar 

  • Dekker GA, Sibai BM (1998) Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol 179:1359–1375

    CAS  PubMed  Google Scholar 

  • Delahanty RJ, Beeghly-Fadiel A, Xiang YB, Long J, Cai Q, Wen W, Xu WH, Cai H, He J, Gao YT, Zheng W, Shu XO (2011) Association of obesity-related genetic variants with endometrial cancer risk: a report from the Shanghai Endometrial Cancer Genetics Study. Am J Epidemiol 174:1115–1126

    PubMed Central  PubMed  Google Scholar 

  • Di Nezza LA, Misajon A, Zhang J, Jobling T, Quinn MA, Ostor AG, Nie G, Lopata A, Salamonsen LA (2002) Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. Cancer 94:1466–1475

    PubMed  Google Scholar 

  • Dileo J, Banerjee R, Whitmore M, Nayak JV, Falo LD Jr, Huang L (2003) Lipid-protamine-DNA-mediated antigen delivery to antigen-presenting cells results in enhanced anti-tumor immune responses. Mol Ther 7:640–648

    CAS  PubMed  Google Scholar 

  • Doherty JA, Weiss NS, Freeman RJ, Dightman DA, Thornton PJ, Houck JR, Voigt LF, Rossing MA, Schwartz SM, Chen C (2005) Genetic factors in catechol estrogen metabolism in relation to the risk of endometrial cancer. Cancer Epidemiol Biomarkers Prev 14:357–366

    CAS  PubMed  Google Scholar 

  • Dowsett M, Dunbier AK (2008) Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res 14:8019–8026

    CAS  PubMed  Google Scholar 

  • Duley L (2009) The global impact of pre-eclampsia and eclampsia. Semin Perinatol 33:130–137

    PubMed  Google Scholar 

  • Eaton DL, Gallagher EP, Bammler TK, Kunze KL (1995) Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics 5:259–274

    CAS  PubMed  Google Scholar 

  • Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, Boyd J, Reis-Filho JS, Ashworth A (2008) Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451:1111–1115

    CAS  PubMed  Google Scholar 

  • Evans JP, Skrzynia C, Burke W (2001) The complexities of predictive genetic testing. BMJ 322:1052–1056

    CAS  PubMed Central  PubMed  Google Scholar 

  • Ferrara N, Vis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18:4–25

    CAS  PubMed  Google Scholar 

  • Ferrara N, Houck K, Jakeman L, Leung DW (1992) Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 13:18–32

    CAS  PubMed  Google Scholar 

  • Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, Singh GM, Gutierrez HR, Lu Y, Bahalim AN, Farzadfar F, Riley LM, Ezzati M (2011) National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 377:557–567

    PubMed  Google Scholar 

  • Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, A'Hern R, Tutt A, Ashworth A, Stone J, Carmichael J, Schellens JH, de Bono JS, Kaye SB (2010) Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 28:2512–2519

    CAS  PubMed  Google Scholar 

  • Franchim CS, Sass N, Mattar R, Pendeloski KP, Lin LH, Torloni MR, Daher S (2011) Inflammatory mediators gene polymorphisms in preeclampsia. Hypertens Pregnancy 30:338–346

    CAS  PubMed  Google Scholar 

  • Freathy RM, Bennett AJ, Ring SM, Shields B, Groves CJ, Timpson NJ, Weedon MN, Zeggini E, Lindgren CM, Lango H, Perry JR, Pouta A, Ruokonen A, Hypponen E, Power C, Elliott P, Strachan DP, Jarvelin MR, Smith GD, McCarthy MI, Frayling TM, Hattersley AT (2009) Type 2 diabetes risk alleles are associated with reduced size at birth. Diabetes 58:1428–1433

    CAS  PubMed Central  PubMed  Google Scholar 

  • Freathy RM, Hayes MG, Urbanek M, Lowe LP, Lee H, Ackerman C, Frayling TM, Cox NJ, Dunger DB, Dyer AR, Hattersley AT, Metzger BE, Lowe WL Jr (2010) Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: common genetic variants in GCK and TCF7L2 are associated with fasting and postchallenge glucose levels in pregnancy and with the new consensus definition of gestational diabetes mellitus from the International Association of Diabetes and Pregnancy Study Groups. Diabetes 59:2682–2689

    CAS  PubMed Central  PubMed  Google Scholar 

  • Freedman AN, Sansbury LB, Figg WD, Potosky AL, Weiss Smith SR, Khoury MJ, Nelson SA, Weinshilboum RM, Ratain MJ, McLeod HL, Epstein RS, Ginsburg GS, Schilsky RL, Liu G, Flockhart DA, Ulrich CM, Davis RL, Lesko LJ, Zineh I, Randhawa G, Ambrosone CB, Relling MV, Rothman N, Xie H, Spitz MR, Ballard-Barbash R, Doroshow JH, Minasian LM (2010) Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst 102:1698–1705

    PubMed Central  PubMed  Google Scholar 

  • Gadducci A, Di Cristofano C, Zavaglia M, Giusti L, Menicagli M, Cosio S, Naccarato AG, Genazzani AR, Bevilacqua G, Cavazzana AO (2006) P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome. Anticancer Res 26:687–693

    CAS  PubMed  Google Scholar 

  • Galic V, Willner J, Wollan M, Garg R, Garcia R, Goff BA, Gray HJ, Swisher EM (2007) Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas. Genes Chromosomes Cancer 46:239–247

    CAS  PubMed  Google Scholar 

  • Garovic VD, Hayman SR (2007) Hypertension in pregnancy: an emerging risk factor for cardiovascular disease. Nat Clin Pract Nephrol 3:613–622

    PubMed  Google Scholar 

  • Gelderman KA, Tomlinson S, Ross GD, Gorter A (2004) Complement function in mAb- mediated cancer immunotherapy. Trends Immunol 25:158–164

    CAS  PubMed  Google Scholar 

  • Goetz MP, Suman VJ, Couch FJ, Ames MM, Rae JM, Erlander MG, Ma XJ, Sgroi DC, Reynolds CA, Lingle WL, Weinshilboum RM, Flockhart DA, Desta Z, Perez EA, Ingle JN (2008) Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance. Clin Cancer Res 14:5864–5868

    CAS  PubMed Central  PubMed  Google Scholar 

  • Goldenberg RL, Culhane JF, Iams JD, Romero R (2008) Epidemiology and causes of preterm birth. Lancet 371:75–84

    PubMed  Google Scholar 

  • Goodman MT, McDuffie K, Guo C, Terada K, Donlon TA (2001) CYP17 genotype and ovarian cancer: a null case-control study. Cancer Epidemiol Biomarkers Prev 10:563–564

    CAS  PubMed  Google Scholar 

  • Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385–427

    CAS  PubMed  Google Scholar 

  • Gradhand U, Kim RB (2008) Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2). Drug Metab Rev 40:317–354

    CAS  PubMed  Google Scholar 

  • Graesslin O, Cortez A, Fauvet R, Lorenzato M, Birembaut P, Darai E (2006a) Metalloproteinase-2, -7 and -9 and tissue inhibitor of metalloproteinase-1 and -2 expression in normal, hyperplastic and neoplastic endometrium: a clinical-pathological correlation study. Ann Oncol 17:637–645

    CAS  PubMed  Google Scholar 

  • Graesslin O, Cortez A, Uzan C, Birembaut P, Quereux C, Darai E (2006b) Endometrial tumor invasiveness is related to metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expressions. Int J Gynecol Cancer 16:1911–1917

    CAS  PubMed  Google Scholar 

  • Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, Helgason A, Stefansson H, Emilsson V, Helgadottir A, Styrkarsdottir U, Magnusson KP, Walters GB, Palsdottir E, Jonsdottir T, Gudmundsdottir T, Gylfason A, Saemundsdottir J, Wilensky RL, Reilly MP, Rader DJ, Bagger Y, Christiansen C, Gudnason V, Sigurdsson G, Thorsteinsdottir U, Gulcher JR, Kong A, Stefansson K (2006) Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 38:320–323

    CAS  PubMed  Google Scholar 

  • Green H, Soderkvist P, Rosenberg P, Horvath G, Peterson C (2006) mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res 12:854–859

    CAS  PubMed  Google Scholar 

  • Green H, Soderkvist P, Rosenberg P, Mirghani RA, Rymark P, Lundqvist EA, Peterson C (2009) Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer. Basic Clin Pharmacol Toxicol 104:130–137

    CAS  PubMed  Google Scholar 

  • Grenetier S, Bouchoux C, Goguel V (2006) CTD kinase I is required for the integrity of the rDNA tandem array. Nucleic Acids Res 34:4996–5006

    CAS  PubMed Central  PubMed  Google Scholar 

  • Grimm SW, Dyroff MC (1997) Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase. Drug Metab Dispos 25:598–602

    CAS  PubMed  Google Scholar 

  • Groenewoud MJ, Dekker JM, Fritsche A, Reiling E, Nijpels G, Heine RJ, Maassen JA, Machicao F, Schafer SA, Haring HU, t Hart LM, van Haeften TW (2008) Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps. Diabetologia 51:1659–1663

    CAS  PubMed  Google Scholar 

  • Hakli T, Romppanen EL, Hiltunen M, Helisalmi S, Punnonen K, Heinonen S (2003) Endothelial nitric oxide synthase polymorphism in preeclampsia. J Soc Gynecol Investig 10:154–157

    CAS  PubMed  Google Scholar 

  • Hall JM, Lee MK (1990) Linkage of early onset familial breast cancer to chromosome 17q21. Science 250:1684–1689

    CAS  PubMed  Google Scholar 

  • Hayes CL, Spink DC, Spink BC, Cao JQ, Walker NJ, Sutter TR (1996) 17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc Natl Acad Sci U S A 93:9776–9781

    CAS  PubMed Central  PubMed  Google Scholar 

  • Helgason A, Palsson S, Thorleifsson G, Grant SF, Emilsson V, Gunnarsdottir S, Adeyemo A, Chen Y, Chen G, Reynisdottir I, Benediktsson R, Hinney A, Hansen T, Andersen G, Borch-Johnsen K et al (2007) Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet 39:218–225

    CAS  PubMed  Google Scholar 

  • Henderson BE, Feigelson HS (2000) Hormonal carcinogenesis. Carcinogenesis 21:427–433

    CAS  PubMed  Google Scholar 

  • Henderson BE, Ross RK, Pike MC, Cassagrande JT (1982) Endogenous hormones as a major factor in human cancer. Cancer Res 24:3232–3239

    Google Scholar 

  • Henderson BE, Ross RK, Bernstein L (1988) Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 48:246

    CAS  PubMed  Google Scholar 

  • Heubner M, Wimberger P, Riemann K, Kasimir-Bauer S, Otterbach F, Kimmig R, Siffert W (2010) The CYP1A1 Ile462Val polymorphism and platinum resistance of epithelial ovarian neoplasms. Oncol Res 18:343–347

    PubMed  Google Scholar 

  • Hillermann R, Carelse K, Gebhardt GS (2005) The Glu298Asp variant of the endothelial nitric oxide synthase gene is associated with an increased risk for abruptio placentae in pre-eclampsia. J Hum Genet 50:415–419

    CAS  PubMed  Google Scholar 

  • Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97:3473–3478

    CAS  PubMed Central  PubMed  Google Scholar 

  • Hunter KW et al (2001) Predisposition to efficient mammary tumor metastatic progression is linked to the breast cancer metastasis suppressor gene Brms1. Cancer Res 61:8866–8872

    CAS  PubMed  Google Scholar 

  • Hurvitz SA, Pegram MD, Lin L-S, Chan DS, Allen HJ, Dichmann RA, Hagenstad CT, Barstis J, Hermann RC, Hu EH, Moroose RL, Thomas SP, Vogel CL, Ryba N, Elashoff D (2009) Final results of a phase II trial evaluating trastuzumab and bevacizumab as first line treatment of HER2-amplified advanced breast cancer. Cancer Res 69:854

    Google Scholar 

  • Indermaur MD, Xiong Y, Kamath SG, Boren T, Hakam A, Wenham RM, Apte SM, Lancaster JM (2010) Genomic-directed targeted therapy increases endometrial cancer cell sensitivity to doxorubicin. Am J Obstet Gynecol 203:158.e1–158.e40

    Google Scholar 

  • Ingle JN, Suman VJ (2005) Aromatase inhibitors for therapy of advanced breast cancer. J Steroid Biochem Mol Biol 95:113–119

    CAS  PubMed  Google Scholar 

  • Ingle JN, Suman VJ, Rowland KM, Mirchandani D, Bernath AM, Camoriano JK, Fishkin PA, Nikcevich DA, Perez EA (2006) Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol 24:1052–1056

    CAS  PubMed  Google Scholar 

  • Ingle JN, Tu D, Pater JL, Muss HB, Martino S, Robert NJ, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE (2008) Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol 19:877–882

    CAS  PubMed  Google Scholar 

  • Irani RA, Xia Y (2008) The functional role of the renin-angiotensin system in pregnancy and preeclampsia. Placenta 29:763–771

    CAS  PubMed Central  PubMed  Google Scholar 

  • Isaka K, Nishi H, Nakai H, Nakada T, Feng Li Y, Ebihara Y, Takayama M (2003) Matrix metalloproteinase-26 is expressed in human endometrium but not in endometrial carcinoma. Cancer 97:79–89

    CAS  PubMed  Google Scholar 

  • Ishigami T, Tamura K, Fujita T, Kobayashi I, Hibi K, Kihara M, Toya Y, Ochiai H, Umemura S (1999) Angiotensinogen gene polymorphism near transcription start site and blood pressure: role of a T-to-C transition at intron I. Hypertension 34:430–434

    CAS  PubMed  Google Scholar 

  • Itamochi H, Kigawa J, Sultana H, Iba T, Akeshima R, Kamazawa S, Kanamori Y, Terakawa N (2002) Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary. Jpn J Cancer Res 93:723–728

    CAS  PubMed  Google Scholar 

  • Ito K (2007) Hormone replacement therapy and cancers: the biological roles of estrogen and progestin in tumorigenesis are different between the endometrium and breast. Tohoku J Exp Med 212:1–12

    CAS  PubMed  Google Scholar 

  • Ji LD, Zhang LN, Shen P, Wang P, Zhang YM, Xing WH, Xu J (2010) Association of angiotensinogen gene M235T and angiotensin-converting enzyme gene I/D polymorphisms with essential hypertension in Han Chinese population: a meta-analysis. J Hypertens 28:419–428

    CAS  PubMed  Google Scholar 

  • Kamazawa S, Kigawa J, Kanamori Y, Itamochi H, Sato S, Iba T, Terakawa N (2002) Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol Oncol 86:171–176

    CAS  PubMed  Google Scholar 

  • Kang S, Ju W, Kim JW, Park NH, Song YS, Kim SC, Park SY, Kang SB, Lee HP (2006) Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer. Exp Mol Med 38:320–324

    CAS  PubMed  Google Scholar 

  • Karahan N, Guney M, Baspinar S, Oral B, Kapucuoglu N, Mungan T (2007) Expression of gelatinase (MMP-2 and MMP-9) and cyclooxygenase-2 (COX-2) in endometrial carcinoma. Eur J Gynaecol Oncol 28:184–188

    CAS  PubMed  Google Scholar 

  • Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P (1990) Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 9:1603–1614

    CAS  PubMed Central  PubMed  Google Scholar 

  • Kautzky-Willer A, Prager R, Waldhausl W, Pacini G, Thomaseth K, Wagner OF, Ulm M, Streli C, Ludvik B (1997) Pronounced insulin resistance and inadequate beta-cell secretion characterize lean gestational diabetes during and after pregnancy. Diabetes Care 20:1717–1723

    CAS  PubMed  Google Scholar 

  • Khrunin A, Ivanova F, Moisseev A, Khokhrin D, Sleptsova Y, Gorbunova V, Limborska S (2012) Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins. Pharmacogenomics 13:171–178

    CAS  PubMed  Google Scholar 

  • Kim S, Misra A (2007) SNP genotyping: technologies and biomedical applications. Annu Rev Biomed Eng 9:289–320

    CAS  PubMed  Google Scholar 

  • Kim YJ, Park BH, Park H, Jung SC, Pang MG, Ryu HM, Lee KS, Eom SM, Park HY (2008) No association of the genetic polymorphisms of endothelial nitric oxide synthase, dimethylarginine dimethylaminohydrolase, and vascular endothelial growth factor with preeclampsia in Korean populations. Twin Res Hum Genet 11:77–83

    PubMed  Google Scholar 

  • Kim JY, Cheong HS, Park BL, Baik SH, Park S, Lee SW, Kim MH, Chung JH, Choi JS, Kim MY, Yang JH, Cho DH, Shin HD, Kim SH (2011) Melatonin receptor 1 B polymorphisms associated with the risk of gestational diabetes mellitus. BMC Med Genet 12:82

    CAS  PubMed Central  PubMed  Google Scholar 

  • King CR, Kraus MH, Aaronson SA (1985) Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229:974–976

    CAS  PubMed  Google Scholar 

  • Kiyohara C, Nakanishi Y, Inutsuka S, Takayama K, Hara N, Motohiro A, Tanaka K, Kono S, Hirohata T (1998) The relationship between CYP1A1 aryl hydrocarbon hydroxylase activity and lung cancer in a Japanese population. Pharmacogenetics 8:315–323

    CAS  PubMed  Google Scholar 

  • Kleinbongard P, Dejam A, Lauer T, Rassaf T, Schindler A, Picker O, Scheeren T, Godecke A, Schrader J, Schulz R, Heusch G, Schaub GA, Bryan NS, Feelisch M, Kelm M (2003) Plasma nitrite reflects constitutive nitric oxide synthase activity in mammals. Free Radic Biol Med 35:790–796

    CAS  PubMed  Google Scholar 

  • Konecny G, Untch M, Pegram M (1999) Herceptin in the treatment of metastatic breast cancer. Gynäkolog 32:624–631

    Google Scholar 

  • Konig M, Shuldiner AR (2012) The genetic interface between gestational diabetes and type 2 diabetes. J Matern Fetal Neonatal Med 25:36–40

    PubMed  Google Scholar 

  • Kristensen VN, Harada N, Yoshimura N, Haraldsen E, Lonning PE, Erikstein B, Karesen R, Kristensen T, Borresen-Dale AL (2000) Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene 19:1329–1333

    CAS  PubMed  Google Scholar 

  • Kuhl C (1991) Aetiology of gestational diabetes. Baillieres Clin Obstet Gynaecol 5:279–292

    CAS  PubMed  Google Scholar 

  • Kupferminc MJ (2005) Thrombophilia and pregnancy. Curr Pharm Des 11:735–748

    CAS  PubMed  Google Scholar 

  • Kwak SH, Kim SH, Cho YM, Go MJ, Cho YS, Choi SH, Moon MK, Jung HS, Shin HD, Kang HM, Cho NH, Lee IK, Kim SY, Han BG, Jang HC, Park KS (2012) A genome-wide association study of gestational diabetes mellitus in Korean women. Diabetes 61:531–541

    CAS  PubMed Central  PubMed  Google Scholar 

  • Laird SM, Dalton CF, Okon MA, Bunning RA, Marshall R, Li TC (1999) Metalloproteinases and tissue inhibitor of metalloproteinase 1 (TIMP-1) in endometrial flushings from pre- and post-menopausal women and from women with endometrial adenocarcinoma. J Reprod Fertil 115:225–232

    CAS  PubMed  Google Scholar 

  • LaMarca BD, Ryan MJ, Gilbert JS, Murphy SR, Granger JP (2007) Inflammatory cytokines in the pathophysiology of hypertension during preeclampsia. Curr Hypertens Rep 9:480–485

    CAS  PubMed  Google Scholar 

  • Lapolla A, Dalfra MG, Fedele D (2009) Diabetes related autoimmunity in gestational diabetes mellitus: is it important? Nutr Metab Cardiovasc Dis 19:674–682

    CAS  PubMed  Google Scholar 

  • Lauenborg J, Grarup N, Damm P, Borch-Johnsen K, Jorgensen T, Pedersen O, Hansen T (2009) Common type 2 diabetes risk gene variants associate with gestational diabetes. J Clin Endocrinol Metab 94:145–150

    CAS  PubMed  Google Scholar 

  • Lee W, Lockhart AC, Kim RB, Rothenberg ML (2005) Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist 10:104–111

    CAS  PubMed  Google Scholar 

  • Lee E, Hsu C, Haiman CA, Razavi P, Horn-Ross PL, Van Den Berg D, Bernstein L, Le Marchand L, Henderson BE, Setiawan VW, Ursin G (2010) Genetic variation in the progesterone receptor gene and risk of endometrial cancer: a haplotype-based approach. Carcinogenesis 31:1392–1399

    CAS  PubMed Central  PubMed  Google Scholar 

  • Levesque S, Moutquin JM, Lindsay C, Roy MC, Rousseau F (2004) Implication of an AGT haplotype in a multigene association study with pregnancy hypertension. Hypertension 43:71–78

    CAS  PubMed  Google Scholar 

  • Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K (2000) Environmental and heritable factors in the causation of cancer–analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343:78–85

    CAS  PubMed  Google Scholar 

  • Liehr JG, Ricci MJ, Jefcoate CR, Hannigan EV, Hokanson JA, Zhu BT (1995) 4-Hydroxylation of estradiol by human uterine myometrium and myoma microsomes: implications for the mechanism of uterine tumorigenesis. Proc Natl Acad Sci U S A 92:9220–9224

    CAS  PubMed Central  PubMed  Google Scholar 

  • Lin R, Lei Y, Yuan Z, Ju H, Li D (2012) Angiotensinogen gene M235T and T174M polymorphisms and susceptibility of pre-eclampsia: a meta-analysis. Ann Hum Genet 76:377–386

    CAS  PubMed  Google Scholar 

  • Lindheimer MD, Taler SJ, Cunningham FG (2010) Hypertension in pregnancy. J Am Soc Hypertens 4:68–78

    CAS  PubMed  Google Scholar 

  • Lundberg JO, Weitzberg E, Gladwin MT (2008) The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov 7:156–167

    CAS  PubMed  Google Scholar 

  • Martin CM, Kehoe L, Spillane CO, O'Leary JJ (2007) Gene discovery in cervical cancer: towards diagnostic and therapeutic biomarkers. Mol Diagn Ther 11:277–290

    CAS  PubMed  Google Scholar 

  • Marzolini C, Paus E, Buclin T, Kim RB (2004) Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75:13–33

    CAS  PubMed  Google Scholar 

  • McGrath M, Hankinson SE, Arbeitman L, Colditz GA, Hunter DJ, De Vivo I (2004) Cytochrome P450 1B1 and catechol-O-methyltransferase polymorphisms and endometrial cancer susceptibility. Carcinogenesis 25:559–565

    CAS  PubMed  Google Scholar 

  • Medeiros R, Pereira D, Afonso N, Palmeira C, Faleiro C, Afonso-Lopes C, Freitas-Silva M, Vasconcelos A, Costa S, Osorio T, Lopes C (2003) Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome. Int J Clin Oncol 8:156–161

    CAS  PubMed  Google Scholar 

  • Meehan KL, Rainczuk A, Salamonsen LA, Stephens AN (2010) Proteomics and the search for biomarkers of female reproductive diseases. Reproduction 140:505–519

    CAS  PubMed  Google Scholar 

  • Meekins JW, Pijnenborg R, Hanssens M, McFadyen IR, van Asshe A (1994) A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet Gynaecol 101:669–674

    CAS  PubMed  Google Scholar 

  • Metzger IF, Souza-Costa DC, Marroni AS, Nagassaki S, Desta Z, Flockhart DA, Tanus-Santos JE (2005) Endothelial nitric oxide synthase gene haplotypes associated with circulating concentrations of nitric oxide products in healthy men. Pharmacogenet Genomics 15:565–570

    CAS  PubMed  Google Scholar 

  • Metzger IF, Sertorio JT, Tanus-Santos JE (2007) Modulation of nitric oxide formation by endothelial nitric oxide synthase gene haplotypes. Free Radic Biol Med 43:987–992

    CAS  PubMed  Google Scholar 

  • Middeldorp S (2007) Pregnancy failure and heritable thrombophilia. Semin Hematol 44:93–97

    PubMed  Google Scholar 

  • Mikhailova ON, Gulyaeva LF, Prudnikov AV, Gerasimov AV, Krasilnikov SE (2006) Estrogen-metabolizing gene polymorphisms in the assessment of female hormone-dependent cancer risk. Pharmacogenomics J 6:189–193

    CAS  PubMed  Google Scholar 

  • Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cichran C, Bennett LM, Ding W et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71

    CAS  PubMed  Google Scholar 

  • Milano G, Etienne MC (1994) Dihydropyrimidine dehydrogenase (DPD) and clinical pharmacology of 5-fluorouracil (review). Anticancer Res 14:2295–2297

    CAS  PubMed  Google Scholar 

  • Milano G, Etienne MC, Pierrefite V et al (1999) Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 79:627–630

    CAS  PubMed Central  PubMed  Google Scholar 

  • Misugi F, Sumi T, Okamoto E, Nobeyama H, Hattori K, Yoshida H, Matsumoto Y, Yasui T, Honda K, Ishiko O (2005) Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in uterine endometrial carcinoma and a correlation between expression of matrix metalloproteinase-7 and prognosis. Int J Mol Med 16:541–546

    CAS  PubMed  Google Scholar 

  • Modugno F, Weissfeld JL, Trump DL, Zmuda JM, Shea P, Cauley JA, Ferrell RE (2001) Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. Clin Cancer Res 7:3092–3096

    CAS  PubMed  Google Scholar 

  • Monaghan H, MacWhinnie N, Williams AR (2007) The role of matrix metalloproteinases-2, -7 and -9 and beta-catenin in high grade endometrial carcinoma. Histopathology 50:348–357

    CAS  PubMed  Google Scholar 

  • Moreno-Bueno G, Sanchez-Estevez C, Cassia R, Rodriguez-Perales S, Diaz-Uriarte R, Dominguez O, Hardisson D, Andujar M, Prat J, Matias-Guiu X, Cigudosa JC, Palacios J (2003) Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res 63:5697–5702

    CAS  PubMed  Google Scholar 

  • Myatt L, Webster RP (2009) Vascular biology of preeclampsia. J Thromb Haemost 7:375–384

    CAS  PubMed  Google Scholar 

  • Napolitano M, Miceli F, Calce A, Vacca A, Gulino A, Apa R, Lanzone A (2000) Expression and relationship between endothelin-1 messenger ribonucleic acid (mRNA) and inducible/endothelial nitric oxide synthase mRNA isoforms from normal and preeclamptic placentas. J Clin Endocrinol Metab 85:2318–2323

    CAS  PubMed  Google Scholar 

  • Nishioka Y, Kobayashi K, Sagae S, Ishioka S, Nishikawa A, Matsushima M, Kanamori Y, Minaguchi T, Nakamura Y, Tokino T, Kudo R (2000) A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter in endometrial carcinomas. Japanese J Cancer Res 91:612–615

    CAS  Google Scholar 

  • Nunobiki O, Ueda M, Toji E, Yamamoto M, Akashi K, Sato N et al (2011) Genetic polymorphism of cancer susceptibility genes and HPV infection in cervical carcinogenesis. Pathol Res Int 2011:364069

    Google Scholar 

  • Obata H, Yahata T, Quan J, Sekine M, Tanaka K (2006) Association between single nucleotide polymorphisms of drug resistance-associated genes and response to chemotherapy in advanced ovarian cancer. Anticancer Res 26:2227–2232

    CAS  PubMed  Google Scholar 

  • O’Brien C, Cavet G, Pandita A, Hu X, Haydu L, Mohan S, Toy K, Rivers CS, Modrusan Z, Amler LC, Lackner MR (2008) Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer. Cancer Res 68:5380–5389

    PubMed  Google Scholar 

  • Olopade OI, Grushko TA, Nanda R, Huo D (2008) Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res 14:7988–7999

    CAS  PubMed  Google Scholar 

  • O’Mara TA, Clements JA, Spurdle AB (2009) The use of predictive or prognostic genetic biomarkers in endometrial and other hormone-related cancers: justification for extensive candidate gene single nucleotide polymorphism studies of the matrix metalloproteinase family and their inhibitors. Cancer Epidemiol Biomarkers Prev 18:2352–2365

    PubMed  Google Scholar 

  • O’Mara TA, Fahey P, Ferguson K, Marquart L, Lambrechts D, Despierre E, Vergote I, Amant F, Hall P, Liu J, Czene K, Rebbeck TR, Ahmed S, Dunning AM, Gregory CS, Shah M, Webb PM, Spurdle AB (2011) Progesterone receptor gene variants and risk of endometrial cancer. Carcinogenesis 32:331–335

    PubMed Central  PubMed  Google Scholar 

  • Osborne CK, Wiebe VJ, McGuire WL, Ciocca DR, DeGregorio MW (1992) Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. J Clin Oncol 10:304–310

    CAS  PubMed  Google Scholar 

  • Papadopoulou A, Lynch KF, Shaat N, Hakansson R, Ivarsson SA, Berntorp K, Agardh CD, Lernmark A (2011) Gestational diabetes mellitus is associated with TCF7L2 gene polymorphisms independent of HLA-DQB1*0602 genotypes and islet cell autoantibodies. Diabet Med 28:1018–1027

    CAS  PubMed Central  PubMed  Google Scholar 

  • Papanicolaou GN (1942) A new procedure for staining vaginal smears. Science 95:438–439

    CAS  PubMed  Google Scholar 

  • Papazoglou D, Galazios G, Koukourakis MI, Panagopoulos I, Kontomanolis EN, Papatheodorou K, Maltezos E (2004) Vascular endothelial growth factor gene polymorphisms and pre-eclampsia. Mol Hum Reprod 10:321–324

    CAS  PubMed  Google Scholar 

  • Pappa KI, Gazouli M, Economou K, Daskalakis G, Anastasiou E, Anagnou NP, Antsaklis A (2011) Gestational diabetes mellitus shares polymorphisms of genes associated with insulin resistance and type 2 diabetes in the Greek population. Gynecol Endocrinol 27:267–272

    CAS  PubMed  Google Scholar 

  • Park YG, Zhao X, Lesueur F, Lowy DR, Lancaster M, Pharoah P, Qian X, Hunter KW (2005) Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Nat Genet 37:1055–1062

    CAS  PubMed Central  PubMed  Google Scholar 

  • Paynter RA, Hankinson SE, Colditz GA, Hunter DJ, De Vivo I (2004) No evidence of a role for PPAR gamma Pro12Ala polymorphism in endometrial cancer susceptibility. Pharmacogenetics 14:851–856

    CAS  PubMed  Google Scholar 

  • Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D (1999) Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18:2241–2251

    CAS  PubMed  Google Scholar 

  • Penson RT, Oliva E, Skates SJ, Glyptis T, Fuller AF Jr, Goodman A, Seiden MV (2004) Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol 93:98–106

    CAS  PubMed  Google Scholar 

  • Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359:572–577

    CAS  PubMed  Google Scholar 

  • Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ (1994) Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9:1829–1838

    CAS  PubMed  Google Scholar 

  • Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ (1995) HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10:2435–2446

    CAS  PubMed  Google Scholar 

  • Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ (1998) Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 17:2235–2249

    CAS  PubMed  Google Scholar 

  • Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ (1999) Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 59:1347–1355

    CAS  PubMed  Google Scholar 

  • Pitot HC, Loeb DD (2002) Fundamentals of oncology, 4th edn. Marcel Dekker Publisher/Informa Healthcare, New York

    Google Scholar 

  • Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, Danyluk J, Godolphin W, Sliwkowski M, Akita R et al (1993) Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53:4960–4970

    CAS  PubMed  Google Scholar 

  • Raftogianis RB, Wood TC, Otterness DM, Van Loon JA, Weinshilboum RM (1997) Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotype. Biochem Biophys Res Commun 239:298–304

    CAS  PubMed  Google Scholar 

  • Raftogianis R, Creveling C, Weinshilboum R, Weisz J (2000) Estrogen metabolism by conjugation. J Natl Cancer Inst Monogr 27:113–124

    Google Scholar 

  • Rahimi Z, Mozafari H, Parsian A (2013) Preeclampsia and angiotensin converting enzyme (ACE) I/D and angiotensin II type-1 receptor (AT1R) A1166C polymorphisms: association with ACE I/D polymorphism. J Renin Angiotensin Aldosterone Syst 14:174–180

    Google Scholar 

  • Ravdin PM, Chamness GC (1995) The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers–a review. Gene 159:19–27

    CAS  PubMed  Google Scholar 

  • Rebbeck TR (1997) Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 6:733–743

    CAS  PubMed  Google Scholar 

  • Rebbeck TR, Troxel AB, Norman S, Bunin G, DeMichele A, Schinnar R, Berlin JA, Strom BL (2007) Pharmacogenetic modulation of combined hormone replacement therapy by progesterone-metabolism genotypes in postmenopausal breast cancer risk. Am J Epidemiol 166:1392–1399

    CAS  PubMed  Google Scholar 

  • Rehman I, Cross SS, Azzouzi AR, Catto JW, Deloulme JC, Larre S, Champigneuille J, Fromont G, Cussenot O, Hamdy FC (2004) S100A6 (Calcyclin) is a prostate basal cell marker absent in prostate cancer and its precursors. Br J Cancer 91:739–744

    CAS  PubMed Central  PubMed  Google Scholar 

  • Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E (2000) A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 37:443–448

    CAS  PubMed  Google Scholar 

  • Rieck S, Kaestner KH (2010) Expansion of beta-cell mass in response to pregnancy. Trends Endocrinol Metab 21:151–158

    CAS  PubMed Central  PubMed  Google Scholar 

  • Rutter JL, Mitchell TI, Buttice G, Meyers J, Gusella JF, Ozelius LJ, Brinckerhoff CE (1998) A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res 58:5321–5325

    CAS  PubMed  Google Scholar 

  • Rylander-Rudqvist T, Wedren S, Jonasdottir G, Ahlberg S, Weiderpass E, Persson I, Ingelman-Sundberg M (2004) Cytochrome P450 1B1 gene polymorphisms and postmenopausal endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 13:1515–1520

    CAS  PubMed  Google Scholar 

  • Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ, Couch FJ, Urban N, Taniguchi T (2008) Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451:1116–1120

    CAS  PubMed Central  PubMed  Google Scholar 

  • Sakai W, Swisher EM, Jacquemont C, Chandramohan KV, Couch FJ, Langdon SP, Wurz K, Higgins J, Villegas E, Taniguchi T (2009) Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res 69:6381–6386

    CAS  PubMed Central  PubMed  Google Scholar 

  • Saldivar JS, Lu KH, Liang D, Gu J, Huang M, Vlastos AT, Follen M, Wu X (2007) Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients. Gynecol Oncol 107:S223–S229

    PubMed  Google Scholar 

  • Sampath D, Greenberger LM, Beyer C, Hari M, Liu H, Baxter M, Yang S, Rios C, Discafani C (2006) Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models. Clin Cancer Res 12:3459–3469

    CAS  PubMed  Google Scholar 

  • Sandrim VC, de Syllos RW, Lisboa HR, Tres GS, Tanus-Santos JE (2007) Influence of eNOS haplotypes on the plasma nitric oxide products concentrations in hypertensive and type 2 diabetes mellitus patients. Nitric Oxide 16:348–355

    CAS  PubMed  Google Scholar 

  • Sandrim VC, Palei AC, Sertorio JT, Cavalli RC, Duarte G, Tanus-Santos JE (2010) Effects of eNOS polymorphisms on nitric oxide formation in healthy pregnancy and in pre-eclampsia. Mol Hum Reprod 16:506–510

    CAS  PubMed  Google Scholar 

  • Sarah R, Esther NM, Shaker A (2010) Mousa Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management. Pharmacogenomics Pers Med 3:129–143

    Google Scholar 

  • Sasaki M, Tanaka Y, Kaneuchi M, Sakuragi N, Dahiya R (2003) CYP1B1 gene polymorphisms have higher risk for endometrial cancer, and positive correlations with estrogen receptor alpha and estrogen receptor beta expressions. Cancer Res 63:3913–3918

    CAS  PubMed  Google Scholar 

  • Schouten LJ, Goldbohm RA, van den Brandt PA (2004) Anthropometry, physical activity, and endometrial cancer risk: results from the Netherlands Cohort Study. J Natl Cancer Inst 96:1635–1638

    PubMed  Google Scholar 

  • Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, Simon W, Eichelbaum M, Brauch H (2007) Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 25:5187–5519

    CAS  PubMed  Google Scholar 

  • Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM, Safgren SL, Kuffel MJ, Ulmer HU, Bolander J, Strick R, Beckmann MW, Koelbl H, Weinshilboum RM, Ingle JN, Eichelbaum M, Schwab M, Brauch H (2009) Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302:1429–1436

    CAS  PubMed  Google Scholar 

  • Scott LJ, Bonnycastle LL, Willer CJ, Sprau AG, Jackson AU, Narisu N, Duren WL, Chines PS, Stringham HM, Erdos MR et al (2006) Association of transcription factor 7-like 2 (TCF7L2) variants with type 2 diabetes in a Finnish sample. Diabetes 55:2649–2653

    CAS  PubMed  Google Scholar 

  • Seraj MJ, Samant RS, Verderame MF, Welch DR (2000) Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13. Cancer Res 60:2764–2769

    CAS  PubMed  Google Scholar 

  • Seremak-Mrozikiewicz A, Drews K, Barlik M, Sieroszewski P, Grzeskowiak E, Mrozikiewicz P (2011) The significance of -786T > C polymorphism of endothelial NO synthase (eNOS) gene in severe preeclampsia. J Matern Fetal Neonatal Med 24:432–436

    CAS  PubMed  Google Scholar 

  • Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P (1993) Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 11:1936–1942

    CAS  PubMed  Google Scholar 

  • Sethi AA, Nordestgaard BG, Tybjaerg-Hansen A (2003) Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease: a meta-analysis. Arterioscler Thromb Vasc Biol 23:1269–1275

    CAS  PubMed  Google Scholar 

  • Shaat N, Lernmark A, Karlsson E, Ivarsson S, Parikh H, Berntorp K, Groop L (2007) A variant in the transcription factor 7-like 2 (TCF7L2) gene is associated with an increased risk of gestational diabetes mellitus. Diabetologia 50:972–979

    CAS  PubMed  Google Scholar 

  • Shah DM (2006) The role of RAS in the pathogenesis of preeclampsia. Curr Hypertens Rep 8:144–152

    CAS  PubMed  Google Scholar 

  • Sharma M, Shubert DE, Lewis J, McGarrigle BP, Bofinger DP, Olson JR (2003) Biotransformation of tamoxifen in a human endometrial explant culture model. Chem Biol Interact 146:237–249

    CAS  PubMed  Google Scholar 

  • Shepard HM, Lewis GD, Sarup JC, Fendly BM, Maneval D, Mordenti J, Figari I, Kotts CE, Palladino MA Jr, Ullrich A et al (1991) Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol 11:117–127

    CAS  PubMed  Google Scholar 

  • Shim JY, Jun JK, Jung BK, Kim SH, Won HS, Lee PR, Kim A (2007) Vascular endothelial growth factor gene +936 C/T polymorphism is associated with preeclampsia in Korean women. Am J Obstet Gynecol 197(271):e271–e274

    Google Scholar 

  • Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Hinshelwood MM, Graham-Lorence S, Amarneh B, Ito Y, Fisher CR, Michael MD et al (1994) Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 15:342–355

    CAS  PubMed  Google Scholar 

  • Sissung TM, Price DK, Sparreboom A, Figg WD (2006) Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention. Mol Cancer Res 4:135–150

    CAS  PubMed  Google Scholar 

  • Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182

    CAS  PubMed  Google Scholar 

  • Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712

    CAS  PubMed  Google Scholar 

  • Smith GC, Pell JP, Walsh D (2001) Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129,290 births. Lancet 357:2002–2006

    CAS  PubMed  Google Scholar 

  • Soini Y, Alarakkola E, Autio-Harmainen H (1997) Expression of messenger RNAs for metalloproteinases 2 and 9, type IV collagen, and laminin in nonneoplastic and neoplastic endometrium. Hum Pathol 28:220–226

    CAS  PubMed  Google Scholar 

  • Stearns V, Davidson NE, Flockhart DA (2004) Pharmacogenetics in the treatment of breast cancer. Pharmacogenomics J 4:143–153

    CAS  PubMed  Google Scholar 

  • Steffensen KD, Waldstrom M, Brandslund I, Jakobsen A (2010) The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecol Oncol 117:109–116

    CAS  PubMed  Google Scholar 

  • Steinthorsdottir V, Thorleifsson G, Reynisdottir I, Benediktsson R, Jonsdottir T, Walters GB, Styrkarsdottir U, Gretarsdottir S, Emilsson V, Ghosh S, Baker A, Snorradottir S, Bjarnason H, Ng MC, Hansen T, Bagger Y, Wilensky RL, Reilly MP, Adeyemo A, Chen Y, Zhou J, Gudnason V, Chen G, Huang H, Lashley K, Doumatey A, So WY, Ma RC, Andersen G, Borch-Johnsen K, Jorgensen T, van Vliet-Ostaptchouk JV, Hofker MH, Wijmenga C, Christiansen C, Rader DJ, Rotimi C, Gurney M, Chan JC, Pedersen O, Sigurdsson G, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K (2007) A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet 39:770–775

    CAS  PubMed  Google Scholar 

  • Stephens M, Smith NJ, Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68:978–989

    CAS  PubMed Central  PubMed  Google Scholar 

  • Sugimoto M, Yoshida S, Kennedy S, Deguchi M, Ohara N, Maruo T (2006) Matrix metalloproteinase-1 and -9 promoter polymorphisms and endometrial carcinoma risk in a Japanese population. J Soc Gynecol Investig 13:523–529

    CAS  PubMed  Google Scholar 

  • Suspitsin EN, Grigoriev MY, Togo AV, Kuligina ES, Belogubova EV, Pozharisski KM, Chagunava OL, Sokolov EP, Theillet C, Berstein LM, Hanson KP, Imyanitov EN (2002) Distinct prevalence of the CYP19 Delta3(TTTA)(7) allele in premenopausal versus postmenopausal breast cancer patients, but not in control individuals. Eur J Cancer 38:1911–1916

    CAS  PubMed  Google Scholar 

  • Takemura M, Azuma C, Kimura T, Tokugawa Y, Miki M, Ono M, Saji F, Tanizawa O (1992) Malignant cell-specific gelatinase activity in human endometrial carcinoma. Cancer 70:147–151

    CAS  PubMed  Google Scholar 

  • Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M, Kurata Y, Kigawa J, Higuchi S, Terakawa N, Otsubo K (2001) Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297:1137–1143

    CAS  PubMed  Google Scholar 

  • Tanaka Y, Sasaki M, Kaneuchi M, Shiina H, Igawa M, Dahiya R (2002) Polymorphisms of the CYP1B1 gene have higher risk for prostate cancer. Biochem Biophys Res Commun 296:820–826

    CAS  PubMed  Google Scholar 

  • Tong D, Fabjani G, Heinze G, Obermair A, Leodolter S, Zeillinger R (2001) Analysis of the human progesterone receptor gene polymorphism progins in Austrian ovarian carcinoma patients. Int J Cancer 95:394–397

    CAS  PubMed  Google Scholar 

  • Tong Y, Lin Y, Zhang Y, Yang J, Liu H, Zhang B (2009) Association between TCF7L2 gene polymorphisms and susceptibility to type 2 diabetes mellitus: a large Human Genome Epidemiology (HuGE) review and meta-analysis. BMC Med Genet 10:15

    PubMed Central  PubMed  Google Scholar 

  • Tran A, Jullien V, Alexandre J, Rey E, Rabillon F, Girre V, Dieras V, Pons G, Goldwasser F, Treluyer JM (2006) Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 79:570–580

    CAS  PubMed  Google Scholar 

  • Tunuguntla R, Ripley D, Sang QX, Chegini N (2003) Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinases TIMP-3 and -4 in benign endometrium and endometrial cancer. Gynecol Oncol 89:453–459

    CAS  PubMed  Google Scholar 

  • Ubeda M, Rukstalis JM, Habener JF (2006) Inhibition of cyclin-dependent kinase 5 activity protects pancreatic beta cells from glucotoxicity. J Biol Chem 281:28858–28864

    CAS  PubMed  Google Scholar 

  • Ueda M, Hung YC, Terai Y, Kanda K, Takehara M, Yamashita H, Yamaguchi H, Akise D, Yasuda M, Nishiyama K, Ueki M (2003) Glutathione S-transferase GSTM1, GSTT1 and p53 codon 72 polymorphisms in human tumor cells. Hum Cell 16:241–251

    PubMed  Google Scholar 

  • Ueland PM, Hustad S, Schneede J, Refsum H, Vollset SE (2001) Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 22:195–201

    CAS  PubMed  Google Scholar 

  • Ueno H, Yamashita K, Azumano I, Inoue M, Okada Y (1999) Enhanced production and activation of matrix metalloproteinase-7 (matrilysin) in human endometrial carcinomas. Int J Cancer 84:470–477

    CAS  PubMed  Google Scholar 

  • Valabrega G, Montemurro F, Aglietta M (2007) Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 18:977–984

    CAS  PubMed  Google Scholar 

  • Vella N, Aiello M, Russo AE, Scalisi A, Spandidos DA, Toffoli G, Sorio R, Libra M, Stivala F (2004) ‘Genetic profiling’ and ovarian cancer therapy. Mol Med Rep 4:771–777

    Google Scholar 

  • Velloso EP, Vieira R, Cabral AC, Kalapothakis E, Santos RA (2007) Reduced plasma levels of angiotensin-(1-7) and renin activity in preeclamptic patients are associated with the angiotensin I- converting enzyme deletion/deletion genotype. Braz J Med Biol Res 40:583–590

    CAS  PubMed  Google Scholar 

  • Vitoratos N, Hassiakos D, Iavazzo C (2012) Molecular mechanisms of preeclampsia. J Pregnancy 2012:298343

    CAS  PubMed Central  PubMed  Google Scholar 

  • Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719–726

    CAS  PubMed  Google Scholar 

  • Wang Y, Nie M, Li W, Ping F, Hu Y, Ma L, Gao J, Liu J (2011) Association of six single nucleotide polymorphisms with gestational diabetes mellitus in a Chinese population. PLoS One 6:e26953

    CAS  PubMed Central  PubMed  Google Scholar 

  • Watanabe RM, Allayee H, Xiang AH, Trigo E, Hartiala J, Lawrence JM, Buchanan TA (2007) Transcription factor 7-like 2 (TCF7L2) is associated with gestational diabetes mellitus and interacts with adiposity to alter insulin secretion in Mexican Americans. Diabetes 56:1481–1485

    CAS  PubMed Central  PubMed  Google Scholar 

  • Widschwendter M, Siegmund KD, Muller HM, Fiegl H, Marth C, Muller-Holzner E, Jones PA, Laird PW (2004) Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 64:3807–3813

    CAS  PubMed  Google Scholar 

  • Williams-Jones B, Corrigan OP (2003) Rhetoric and hype: where’s the ‘ethics’ in pharmacogenomics? Am J Pharmacogenomics 3:375–383

    PubMed  Google Scholar 

  • Xie F, Hu Y, Speert DP, Turvey SE, Peng G, Money DM, Magee LA, von Dadelszen P (2010) Toll-like receptor gene polymorphisms and preeclampsia risk: a case-control study and data synthesis. Hypertens Pregnancy 29:390–398

    CAS  PubMed  Google Scholar 

  • Xu X, Duncan AM, Merz-Demlow BE, Phipps WR, Kurzer MS (1999) Menstrual cycle effects on urinary estrogen metabolites. J Clin Endocrinol Metab 84:3914–3918

    CAS  PubMed  Google Scholar 

  • Xu WH, Long JR, Zheng W, Ruan ZX, Cai Q, Cheng JR, Xiang YB, Shu XO (2009) Association of the progesterone receptor gene with endometrial cancer risk in a Chinese population. Cancer 115:2693–2700

    CAS  PubMed Central  PubMed  Google Scholar 

  • Yamazaki H, Shaw PM, Guengerich FP, Shimada T (1998) Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes. Chem Res Toxicol 11:659–665

    CAS  PubMed  Google Scholar 

  • Yan L, Beckman RA (2005) Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development. Biotechniques 39:565–568

    PubMed  Google Scholar 

  • Yan L, Shu-Ying Y, Shan K, Yip BH, Rong-Miao Z, Na W, Hai-Yan S (2012) Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy. Pharmacogenomics 13:419–427

    PubMed  Google Scholar 

  • Yang X, Dong Y, Zhao J, Sun H, Deng Y, Fan J, Yan Q (2007) Increased expression of human macrophage metalloelastase (MMP-12) is associated with the invasion of endometrial adenocarcinoma. Pathol Res Pract 203:499–505

    CAS  PubMed  Google Scholar 

  • Yoneda K, Tanji Y, Ikeda N, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S (2002) Influence of adjuvant tamoxifen treatment on bone mineral density and bone turnover markers in postmenopausal breast cancer patients in Japan. Cancer Lett 186:223–230

    CAS  PubMed  Google Scholar 

  • Yoshimura M, Yasue H, Nakayama M, Shimasaki Y, Sumida H, Sugiyama S, Kugiyama K, Ogawa H, Ogawa Y, Saito Y, Miyamoto Y, Nakao K (1998) A missense Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese. Hum Genet 103:65–69

    CAS  PubMed  Google Scholar 

  • Yu JJ, Lee KB, Mu C, Li Q, Abernathy TV, Bostick-Bruton F, Reed E (2000) Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 16:555–560

    CAS  PubMed  Google Scholar 

  • Zhao L, Dewan AT, Bracken MB (2012) Association of maternal AGTR1 polymorphisms and preeclampsia: a systematic review and meta-analysis. J Matern Fetal Neonatal Med 25:2676–2680

    Google Scholar 

  • zur Hausen H (2000) Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 92:690–698

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Institute of Engineering and Technology, Panjab University, Chandigarh, India

    Jaspreet Kaur

  2. Biochemistry, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India

    Beenish Rahat & Jyotdeep Kaur

Authors
  1. Jaspreet Kaur
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Beenish Rahat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jyotdeep Kaur
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jyotdeep Kaur .

Editor information

Editors and Affiliations

  1. Centre for Genomics & Applied Gene Technology, Institute of Integrative Omics and Applied Biotechnology (IIOAB), Purba Medinipur, West Bengal, India

    Debmalya Barh

  2. Institute of Life Sciences, B.V. Patel Pharmaceutical Education and Research Development Centre, Ahmedabad University, Ahmedabad, Gujarat, India

    Dipali Dhawan

  3. Policy Centre for Biomedical Research, Translational Health Science and Technology Institute (Department of Biotechnology Institute, Government of India), Office @ National Institute of Immunology, New Delhi, India

    Nirmal Kumar Ganguly

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer India

About this chapter

Cite this chapter

Kaur, J., Rahat, B., Kaur, J. (2013). Pharmacogenomics of Gynecological Disorders. In: Barh, D., Dhawan, D., Ganguly, N. (eds) Omics for Personalized Medicine. Springer, New Delhi. https://doi.org/10.1007/978-81-322-1184-6_30

Download citation

Publish with us

Policies and ethics

Search

Navigation